Citius Pharmaceuticals Inc. [NASDAQ: CTXR] traded at a high on 10/13/21, posting a 1.49 gain after which it closed the day’ session at $2.04. The company report on October 13, 2021 that Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777).
Investor Webcast will be held on October 20, 2021 at 8:30 a.m. ET.
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) announced that it will host a webcast on October 20, 2021 at 8:30 a.m. ET to discuss the Company’s previously announced acquisition of I/ONTAK (E7777), an improved formulation of immunotoxin ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
The results of the trading session contributed to over 3418275 shares changing hands. Over the past one week, the price volatility of Citius Pharmaceuticals Inc. stands at 3.74% while the volatility over the past one month is 4.40%.
The market cap for CTXR stock reached $306.59 million, with 137.15 million shares outstanding and 133.67 million shares in the current float. Compared to the average trading volume of 2.85M shares, CTXR reached a trading volume of 3418275 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Citius Pharmaceuticals Inc. [CTXR]?
The Average True Range (ATR) for Citius Pharmaceuticals Inc. is set at 0.10 The Price to Book ratio for the last quarter was 2.04, with the Price to Cash per share for the same quarter was set at 0.77.
How has CTXR stock performed recently?
Citius Pharmaceuticals Inc. [CTXR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.49. With this latest performance, CTXR shares gained by 3.03% in over the last four-week period, additionally plugging by 19.30% over the last 6 months – not to mention a rise of 90.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 49.40, with the RSI for the last a single of trading hit 49.40, and the three-weeks RSI is set at 49.12 for Citius Pharmaceuticals Inc. [CTXR]. The present Moving Average for the last 50 days of trading for this stock 2.01, while it was recorded at 2.05 for the last single week of trading, and 1.99 for the last 200 days.
Citius Pharmaceuticals Inc. [CTXR]: Deeper insight into the fundamentals
Return on Total Capital for CTXR is now -59.46, given the latest momentum, and Return on Invested Capital for the company is -59.42. Return on Equity for this stock declined to -60.46, with Return on Assets sitting at -48.24. When it comes to the capital structure of this company, Citius Pharmaceuticals Inc. [CTXR] has a Total Debt to Total Equity ratio set at 4.02. Additionally, CTXR Total Debt to Total Capital is recorded at 3.86, with Total Debt to Total Assets ending up at 3.09. Long-Term Debt to Equity for the company is recorded at 3.03, with the Long-Term Debt to Total Capital now at 2.91.
Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 32.50 and a Current Ratio set at 32.50.
Insider trade positions for Citius Pharmaceuticals Inc. [CTXR]
There are presently around $51 million, or 21.70% of CTXR stock, in the hands of institutional investors. The top three institutional holders of CTXR stocks are: BLACKROCK INC. with ownership of 8,124,526, which is approximately 321.257% of the company’s market cap and around 8.40% of the total institutional ownership; VANGUARD GROUP INC, holding 5,652,813 shares of the stock with an approximate value of $11.53 million in CTXR stocks shares; and STATE STREET CORP, currently with $4.02 million in CTXR stock with ownership of nearly New of the company’s market capitalization.
Positions in Citius Pharmaceuticals Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 60 institutional holders increased their position in Citius Pharmaceuticals Inc. [NASDAQ:CTXR] by around 15,138,080 shares. Additionally, 15 investors decreased positions by around 913,416 shares, while 6 investors held positions by with 9,096,885 shares. The mentioned changes placed institutional holdings at 25,148,381 shares, according to the latest SEC report filing. CTXR stock had 42 new institutional investments in for a total of 4,303,276 shares, while 10 institutional investors sold positions of 729,691 shares during the same period.